Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.15 USD
-0.06 (-4.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACRS 1.15 -0.06(-4.96%)
Will ACRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRS
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
Other News for ACRS
Aclaris Therapeutics’ ATI-2138: A Hold Rating Amidst Phase 2a Trials and Market Opportunity Assessment
Aclaris Therapeutics (ACRS) Gets a Hold from H.C. Wainwright
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris announces first patient dosed in Phase 2a trial of ATI-2138
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference